MRI contrast developer Epix Pharmaceuticals has received approval from Health Canada's Health Products and Food Branch (HPFB) for its Vasovist blood-pool MR angiography contrast agent.
With the approval, Vasovist is now approved for marketing in 30 countries, according to the Lexington, MA-based firm.
By AuntMinnie.com staff writers
November 6, 2006
Related Reading
Epix nets Australian approval, September 20, 2006
Epix regains Nasdaq symbol, September 15, 2006
FDA rejects Epix appeal, August 28, 2006
Epix, Predix complete merger, August 17, 2006
Epix, Predix shareholders approve merger, August 15, 2006
Copyright © 2006 AuntMinnie.com
